Title: Treatment of Melanoma by Reduction in Clusterin Levels. Number: 20040082534. Filed: Aug. 21, 2003. Lead Inventor: Martin Gleave, Vancouver General Hospital.
The patent application, its abstract states, covers the treatment of melanoma through “reduction in the effective amount of clusterin in melanoma cells … in a mammalian subject, preferably a human.”